Fertility preservation is becoming extremely necessary to help improve the quality of living within female cancer survivors. Despite recommendations that suggest that there should be consideration of preservation fertility before cancer treatments start, there is a lack of regulation in this field. A variety of fertility preservation methods are available, and can be employed separately or together in the same patient to enhance medical performance and therefore to augment efficiency. Oocytes and fetal cryopreservation are indeed well known methods but have restrictions. Although currently perceived as experimental, ovarian tissue cryopreservation has a broader clinical application and the advantage to maintain longer the fertility option. Chemotherapy and radiotherapy have a huge effect on the reproductive potential and the process of fertility preservation should be implemented before these two treatments. The importance of fertility preservation has to be weighed against morbidity and mortality in relation with cancer. A multidisciplinary cooperation between oncologists and reproductive specialists is therefore necessary to increase knowledge and accessibility.